Mobocertinib has not yet been officially listed in Chinese Mainland. When patients need to obtain it through overseas channels, they should pay special attention to the quality and legality of drugs.

1. Domestic listing status

(1) Approval status: According to the existing information, Mobotinib has not been approved by the China National Medical Products Administration and has not yet been included in the list of domestically marketed drugs.

(2) Access: Patients can purchase through compliant cross-border medical channels, but must provide a complete prescription and customs declaration materials.

2 Indications

(1) Treatment scope: This drug is mainly used for non-small cell lung cancer with EGFR exon 20 insertion mutation, and belongs to targeted therapy drugs.

(2) Clinical value: It has significant therapeutic effects on patients with specific gene mutations and is included in the recommended NCCN guidelines.

3. Medication Risk Warning

(1) Quality risk: Cross border drug purchases require verification of drug batch numbers, production dates, and original packaging to avoid counterfeit and inferior products.

(2) Regulatory requirements: According to China's Drug Administration Law, unapproved drugs are not allowed to circulate in the domestic market, and personal use must comply with the limit regulations.